90 results about "Neuropsychiatric disease" patented technology

A method and apparatus for physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, depression, epilepsy, and diabetes. This includes chronically implanted neural and neuromuscular modulators, used to modulate the afferent neurons of the sympathetic nervous system to induce satiety. Furthermore, this includes neuromuscular stimulation of the stomach to effect baseline and intermittent smooth muscle contraction to increase gastric intraluminal pressure, which induces satiety, and stimulate sympathetic afferent fibers, including those in the sympathetic trunk, splanchnic nerves, and greater curvature of the stomach, to augment the perception of satiety.

Disclosed are methods of treating neuropsychiatric diseases, neuromuscular diseases, viral infections, neurodegenerative diseases and ricin poisoning using angiotensin II receptor blockers.

Biomarkers for the diagnosis of neuropsychiatric diseases are presented herein. In particular embodiments, biomarkers are identified that are useful for diagnosing multiple sclerosis, chronic fatigue syndrome, or Neurologic Lyme disease. Also encompassed is a method for diagnosing a patient with a neuropsychiatric disease, such as multiple sclerosis, chronic fatigue syndrome, or Neurologic Lyme disease, by analyzing biological samples isolated from the patient or the patient as a whole to assess levels of the biomarkers described herein.

Disclosed herein is the use of N-desmethylclozapine (NDMC) and related compounds to treat a variety of neuropsychiatric diseases including psychosis. It is shown that NDMC and related compounds are agonists or partial agonists at D2 and D3 dopamine receptors and thus may be effective as a dopamine stabilizing agent, allowing it to be used to treat or provide reduced incidence of Extrapyramidal symptoms (EPS) and / or tardive dyskinesias (TD). Also disclosed is administering NDMC and related compounds in combination with other anti-psychotic agents.

The invention discloses a dynamic brain function connection mode dividing method based on PAC and K-means clustering. The method divides the dynamic function into basic connection modes. The method includes the following steps: conducting pre-processing on resting state magnetic resonance data, extracting the time sequences of brain zones, then adopting the sliding window method in calculating related coefficients between each two of the brain zones, constructing corresponding function connection matrixes, and finally conducting PCA and K-means clustering on the function connection matrixes so as to obtain basic connection modes. According to the invention, the dynamic function connection mode dividing algorithm can effectively and accurately obtain the divided basic function connection modes, not only can capture transition among different basic connection modes, and can provide strategies for further research and prevention and treatment of clinic neurological diseases, such as Schizophrenia, Alzheimer's disease, depression, and etc.

The invention belongs to the field of pharmaceutical chemistry and in particular relates to a benzopyrone derivative and application thereof. The benzopyrone derivative has a structure shown in a formula (I). Discovered by the experiment, the compound can be used for preparing drugs for treating neuropsychiatric diseases.

Compounds of general Formula (I):wherein R1, R2, R3, Ra, A, B and x are as defined herein are inhibitors of protein kinases in particular members of the cyclin-dependent kinase family and / or the glycogen synthase kinase 3 family and are useful in preventing and / or treating any type of pain, inflammatory disorders, cancer, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases, metabolic disorders, renal diseases, neurologic and neuropsychiatric diseases and neurodegenerative diseases.

The present invention discloses a method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or of DP IV-like enzyme activity in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates by DP IV and DP IV-like enzymes. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1–36). As a consequence of the resulting enhanced stability of the endogenous NPY (1–36) caused by the inhibition of DP IV activity, NPY activity is prolonged thereby resulting among other things in functionally active NPY Y1 receptor activity thereby facilitating anti-depressive, anxiolytic, analgesic, anti-hypertension and other neurological effects.

The present invention discloses a method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable attractin inhibitor causes the reduction of activity in the enzyme attraction or in isoforms thereof in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1-36). As a consequence of the resulting enhanced stability of the endogenous NPY (1-36), NPY activity is prolonged thereby resulting among other things in functionally active NPY Y1 receptor activity thereby facilitating antidepressive, anxiolytic, analgesic, t antihypertension and other neurological effects.

The present invention teaches a method and apparatus for physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, depression, epilepsy, and diabetes. This includes chronically implanted neural and neuromuscular modulators, used to modulate the afferent neurons of the sympathetic nervous system to induce satiety as well as to modulate the efferent neurons of the sympathetic nervous system to modulate metabolism, including metabolic rate. Furthermore, this includes neuromuscular stimulation of the stomach to effect baseline and intermittent smooth muscle contraction to increase gastric intraluminal pressure, which induces satiety, and stimulate sympathetic afferent fibers, including those in the sympathetic trunk, splanchnic nerves, and greater curvature of the stomach, to augment the perception of satiety.

Compounds of general formula (I): R1—Wn—Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-Yp—Zq—R2, their stereoisomers, mixtures thereof and / or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and / or prevention of pain, inflammation, itching, neurological, compulsive and / or neuropsychiatric diseases and / or disorders and in processes of treatment and / or care of the skin, hair and / or mucous membranes mediated by neuronal exocytosis.

The present invention discloses a piperazine (piperidine) cyclohexyl derivative and applications of the piperazine (piperidine) cyclohexyl derivative in treatment of neuropsychiatric diseases. According to the present invention, the pharmacological experiment results show that the piperazine (piperidine) cyclohexyl derivative provides high affinity with a dopamine D2 receptor, a dopamine D3 receptor, a serotonin 5-HT1A receptor and a serotonin 5-HT2A receptor, provides good D3 / D2 receptor selectivity and good 5-HT1A / 5-HT2A receptor selectivity, and provides low affinity with alpha receptor; the in vivo test results show that the preferred compound has characteristics of good anti-schizophrenia effect, good pharmacokinetic property, low side effect, low acute toxicity and high safety, and has the development value of being adopted as the novel efficient and low-toxic anti-neuropsychiatric disease; and the piperazine (piperidine) cyclohexyl derivative is a compound represented by the structural general formula (I), or a geometric isomer, an optical isomer, a salt, a hydrate or a solvate thereof. The formula (I) is defined in the specification.

Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and / or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and / or prevention of pain, inflammation, itching, neurological, compulsive and / or neuropsychiatric diseases and / or disorders and in processes of treatment and / or care of the skin, hair and / or mucous membranes mediated by neuronal exocytosis.

The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof. The method is particularly suitable for the treatment of agitation associated with neurodegenerative and / or neuropsychiatric diseases. The present invention also discloses the sublingual administration of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose that is effective to treat agitation or the signs of agitation in a subject, but does not cause significant sedation.

The invention belongs to a dynamic micro-sensor detecting system which is extensively applied to the technical fields of dynamic monitoring on important ingredients of serious diseases, such as neuropsychiatric diseases and diabetes, and biological chip preparation by dynamic DNA synthesis, and the like. The dynamic micro-sensor detecting system comprises a flow cell, a flowing pool, a sensor supporting body and a sensor. On one hand, the system is capable of ensuring full reaction, timely removal of raffinate and convenient assembly, disassembly and clean in a monitoring process under dynamic conditions, on the other hand, selected working electrodes are formed by a modified porous electrode supporting plate with high sensitivity and selectivity on a detected object, thereby being beneficial to change of the electrodes, and adding new serially connected working electrodes to simultaneously detect a plurality of ingredients. The detecting system is beneficial to realize on-line, real-time and quick monitoring and is beneficial to improving the stability, sensitivity and selectivity of a detecting signal in dynamic detection.

The invention belongs to the technical field of medicines and particularly relates to a perampanel sesquihydrate and a preparation method thereof. The perampanel sesquihydrate contains one and a half crystal water. The perampanel sesquihydrate has the advantages that the purity is high; the stability is good, and the moisture absorption and the weight increment are not obvious even at a high humidity condition; by virtue of the perampanel sesquihydrate, the inhibiting effect to the activity of AMPA receptor glutamic acid is increased by about 20%. The invention further relates to application of a composition of the perampanel sesquihydrate in the treatment of neuropsychiatric diseases.

Lithium is regarded as the gold standard comparator and benchmark treatment for mania. One of the problems associated with Lithium is its narrow therapeutic window. Recent attempts to find new drugs with similar therapeutic activities have yielded new chemical entities. However, these potential new drugs have yet to match the many bioactivities attributable to lithium's efficacy for the treatment of neuropsychiatric diseases. Consequently, an intense effort for re-engineering lithium therapeutics using cocrystallization is currently underway. The evaluation of pharmacokinetics of previously unexplored lithium salts with organic anions (lithium salicylate and lithium lactate) has found that these lithium salts exhibit profoundly different pharmacokinetics compared to the more common FDA approved salt, lithium carbonate, in rats. Remarkably, lithium salicylate produced elevated blood and brain levels of lithium beyond 48 hours post-dose without the sharp peak that contributes to the toxicity problems of current lithium therapeutics.

A medicine which comprises a combination of an acetylcholine esterase inhibitor and a 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1H)-one derivative represented by the following general formula (I). It is useful for the treatment of memory disorders accompanying neuropsychiatric diseases and other cognition disorders. Also provided are: a method of treatment of any of these diseases which comprises using a combination of these drugs; and a use of the medicine. (In the formula (I), Het is oxadiazolyl; R<1> is hydrogen, lower alkyl, cyclo(lower alkyl), lower alkenyl, lower alkoxy, (un)substituted aryl, (un)substituted heteroaryl, etc.; and R<2> is hydrogen, lower alkyl, cyclo(lower alkyl), (un)substituted aryl, etc.).

Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof. More specifically, provided is a prodrug that increases the in vivo exposure and enhances the oral absorbability and other mucosal absorbability of a parent compound that acts on group 2 metabotropic glutamate receptors as an agent for the treatment or prevention of diseases in which group 2 metabotropic glutamate receptors are said to be involved, such as: schizophrenia, anxiety disorder and its related diseases, depression, bipolar disorder, epilepsy, developmental disorders, sleep disorders, and other neuropsychiatric diseases; and drug dependence, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, movement disorders associated with muscular rigidity, cerebral ischemia, cerebral insufficiency, spinal cord disorders, cephalopathy, and other neurological diseases.

The application relates to a method of diagnosing neuropsychiatric diseases, eating disorders and / or metabolic diseases, which comprises: (i) measuring the affinity and / or the avidity of antibodies, derived from a biological sample, directed against a biological molecule involved in homeostatic regulation and / or in motivational behavior and / or in emotion; (ii) comparing the affinity value obtained with a control value.

A compound represented by the formula (I), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof:wherein X1 represents N and X2 represents C, or X1 represents C and X2 represents N;Y1 represents CR4 or N;Y2 represents CH or N;wherein both Y1 and Y2 do not represent N at the same time;R1 represents (1) C3-10 branched alkyl which may be substituted or (2) —(CH2)m—NR5R6; R2, R3, and R4 each independently represent H, C1-4 alkyl, a halo-substituted C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, or the like;R5 and R6 each independently represent C1-6 alkyl which may be substituted, or R5 represents H, and R6 represents C3-6 branched alkyl which may be substituted; andAr represents an aromatic ring which may be substituted, is useful as a pharmacologically active ingredient having a CRF antagonistic activity in preventing and / or treating neuropsychiatric diseases, diseases of peripheral organs or the like.

Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof. More specifically, provided is a prodrug that increases the in vivo exposure and enhances the oral absorbability and other mucosal absorbability of a parent compound that acts on group 2 metabotropic glutamate receptors as an agent for the treatment or prevention of diseases in which group 2 metabotropic glutamate receptors are said to be involved, such as: schizophrenia, anxiety disorder and its related diseases, depression, bipolar disorder, epilepsy, developmental disorders, sleep disorders, and other neuropsychiatric diseases; and drug dependence, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, movement disorders associated with muscular rigidity, cerebral ischemia, cerebral insufficiency, spinal cord disorders, cephalopathy, and other neurological diseases.

The invention provides a novel application of a Pinghuwanxing sesquiterpene compound, namely Isonardosinone or kanshone E, of nardostachys chinensis batal.; the Pinghuwanxing sesquiterpene compound of the nardostachys chinensis batal. is obtained from rhizome of the nardostachys chinensis batal., which belongs to valerianaceae nardostachys plants, by separating and purifying; the sesquiterpene compound has a 5-serotonin transporter (SERT) enhanced activity; the sesquiterpene compound, as a rare SERT activity promoter, is applicable to preparing medicines for treating such neuropsychiatric diseases as depression, anxiety disorder, schizophrenia, obsessive-compulsive disorder, neurodegenerative disease, drug addiction and the like as well as medicines for treating such digestive system dysfunction diseases as slow transit constipation, irritable bowel syndrome, functional abdominal distention and the like; and the sesquiterpene compound has an important medicine development value.

An antibody for diagnosis or treatment of neuropsychiatric diseases, in particular schizophrenia, depression or bipolar affective disorders, is characterized in that the antibody recognizes misfolded specific proteins that can be assigned to one of the diseases, and a method for diagnosis by means of antibodies that bind to neuropsychiatric disease-specific proteins.

Disclosed is the use of mesenchymal stem cells (MSCs) and in particular MSCs pretreated with pituitary adenylate cyclase-activating polypeptide (PACAP) or analogs and fragments of PACAP, for treatment of neurodegenerative and psychiatric diseases, and for the improvement of affective and cognitive function in a normal individual or in an individual suffering from a neurodegenerative or neuropsychiatric disease.

The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and / or condition, wherein modulation of D-serine levels, and / or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and / or cognition. For example, the invention provides methods for treating or preventing loss of memory and / or cognition associated with neurodegenerative diseases, such as Alzheimer's disease. The invention further provides methods for preventing loss of neuronal function characteristic of neurodegenerative diseases. In addition, methods are provided for the treatment or prevention of neuropsychiatric diseases (e.g., schizophrenia) and for the treatment or prevention of pain and ataxia.

The invention relates to nardoaristolones B and a preparation method and application thereof. The nardoaristolones B are obtained from rhizomes of valerianaceae nardostachys plant nardostachys chinensis in a separated and purified mode, improve activity of serotonin transporters (SERTs), belong to rare SERT active promoters and can be used for preparing medicine for treating neuropsychiatric diseases such as depression, anxiety disorder, schizophrenia, obsession, neurodegeneration and drug addiction. Meanwhile, the nardoaristolones B can be used for preparing medicine for treating digestion system dysfunction such as an irritable bowl syndrome, slow transit constipation and functional bloating and has important medicine development value.